SAB Biotherapeutics (SABS) Non Operating Income (2021 - 2026)

SAB Biotherapeutics (SABS) has 6 years of Non Operating Income data on file, last reported at $1.1 million in Q1 2026.

• Quarterly Non Operating Income fell 79.75% year-over-year to $1.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $57.8 million (up 620.85% YoY) and the FY2025 annual result came in at $62.2 million, up 606.71% from the prior year.
• Non Operating Income advanced to $1.1 million in Q1 2026, from -$1.1 million in the prior quarter.
• In the past five years, Non Operating Income ranged from a high of $58.1 million in Q3 2025 to a low of -$4.0 million in Q4 2023.
• A 5-year average of $4.6 million and a median of $731248.0 in 2022 frame the typical range for Non Operating Income.
• Annual changes were most pronounced in 2023 — Non Operating Income plunged 36168.02% — and 2024, when it surged 13108.14%.
• Tracing SABS's Non Operating Income over 5 years: stood at $11043.0 in 2022, then sank by 36168.02% to -$4.0 million in 2023, then jumped by 65.21% to -$1.4 million in 2024, then increased by 21.31% to -$1.1 million in 2025, then surged by 203.52% to $1.1 million in 2026.
• The last three Non Operating Income figures came in at $1.1 million (Q1 2026), -$1.1 million (Q4 2025), and $58.1 million (Q3 2025), per Business Quant data.